Mirtazapin Genericon (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Genericon, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients and is formulated for once‑daily administration across the European Union.

GNH USA supplies Mirtazapin Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable bulk shipments and regulatory support for cross‑border procurement. The company adheres to stringent quality standards, ensuring product integrity during storage and transport, and collaborates with regulatory agencies to maintain compliance.

Mirtazapine is an antidepressant that acts on noradrenergic and serotonergic pathways to alleviate depressive symptoms.

- Major depressive disorder: reduces depressive mood, improves sleep and appetite in adult patients. - Treatment‑resistant depression: may be added when first‑line agents are insufficient to achieve remission. - Depressive symptoms associated with chronic medical conditions: helps improve mood and quality of life in patients with comorbid illnesses.

Mirtazapine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction (elevated transaminases) - Suicidal thoughts or behavior, especially early in treatment

When prescribing mirtazapine, clinicians should consider several safety measures to minimise risk.

- Assess hepatic function: evaluate liver enzymes before initiation and monitor periodically. - Monitor weight: counsel patients about potential weight gain and increased appetite. - Screen for suicidal ideation: particularly during the first weeks of therapy. - Avoid abrupt discontinuation: taper the dose to reduce risk of withdrawal symptoms. - Use caution in elderly patients: increased sensitivity to sedation and orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis; a washout period is required. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can raise mirtazapine plasma levels, increasing side‑effect risk. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce mirtazapine concentrations, diminishing therapeutic effect. - Antihistamines: additive sedation may occur. - Lithium: monitor serum lithium levels as mirtazapine may affect renal clearance.